Search the Newsreel

Nutanix Shareholder Notice

Faruqi & Faruqi, LLP is investigating potential claims against Nutanix, Inc. (NASDAQ: NTNX) and encourages investors who lost over $100,000 to contact them before the June 13, 2023 lead plaintiff deadline. The investigation follows disclosures that Nutanix allegedly misused third-party evaluation software for business …

Botanix Pharmaceuticals (ASX: BOT): Healthcare Stock Retreats Amid Broader Sector Weakness

Anixa Biosciences (ANIX) Upgraded to Strong Buy: Here's What You Should Know

Anixa Biosciences (ANIX) has been upgraded to a Zacks Rank #1 (Strong Buy) due to an upward trend in earnings estimates. This upgrade signals an improvement in the company's underlying business and suggests a potential for favorable stock price movement, aligning with the strong …

Anixa Biosciences (ANIX) CEO buys 5,000 common shares

Anixa Biosciences Inc.'s CEO and director, Amit Kumar, purchased 5,000 shares of common stock at $3.46 per share on July 20, 2026. This transaction was an open-market or private purchase, increasing his direct holdings to 640,812 shares. The purchase was not made under a …

Nutanix (NTNX) Stock Falls Amid Market Uptick: What Investors Need to Know

Nutanix (NTNX) closed at $54.19 in the latest trading session, marking a -1.67% move from the prior day. This change lagged the S&P 500's daily gain of 0.89%. Meanwhile, the Dow gained 0.74%, and the Nasdaq, a tech-heavy index, added 1.29%. Heading into today, …

Insider Buying: Titterton Lewis H Jr Acquires Additional Shares of Anixa Biosciences Inc (ANIX)

Titterton Lewis H Jr, a Director at Anixa Biosciences Inc (ANIX), recently purchased 12,000 shares of the company, increasing his total holdings to 986,967 shares. This purchase is part of a trend of insider buying at ANIX, with 8 insider buys and no sells …

Anixa Biosciences (ANIX) director purchases 12,000 shares of common stock

Anixa Biosciences director Lewis H. Titterton Jr. purchased 12,000 shares of common stock on July 20, 2026, at $3.47 per share. This transaction increases his direct holdings to 986,967 shares and was classified as an open market or private purchase. The Form 4 filing …

Anixa Biosciences director buys $9,174 in common stock

Anixa Biosciences director Lewis H. Titterton Jr. purchased 2,797 shares of common stock for $9,174 on July 15, 2026, increasing his direct holdings to 974,967 shares. Despite the stock's recent gain, InvestingPro suggests the company may be overvalued. Anixa Biosciences is also making progress …

Insider Buying: Titterton Lewis H Jr Increases Stake in Anixa Bi

On July 15, 2026, Anixa Biosciences Inc Director Titterton Lewis H Jr purchased 2,797 shares, increasing his total holdings to 974,967 shares. This transaction reflects positive insider sentiment, as he has acquired 15,633 shares over the past year without any sales. The company currently …

Form 4 Anixa Biosciences Inc For: 16 July By Investing.com

This article reports on a Form 4 filing for Anixa Biosciences Inc. on July 16, highlighting the basic announcement without providing further details about the filing's content. It also includes various market data and other news headlines related to the financial sector.

Director Lewis Titterton buys more Anixa Biosciences Inc (ANIX) stock

Anixa Biosciences Inc. director Lewis H. Titterton Jr. purchased 2,797 shares of ANIX common stock on July 15, 2026, at a price of $3.28 per share. This open-market transaction increased his direct holdings to 974,967 shares. The filing was reported on a Form 4, …

Nutanix (NTNX) Stock Declines While Market Improves: Some Information for Investors

Botanix Pharmaceuticals (ASX:BOT): Why This ASX Biotech Stock Is Catching Investor Attention

ANIX Forecast — Price Target — Prediction for 2027

Why Is Nutanix (NTNX) Down 3.8% Since Last Earnings Report?

Botanix Pharmaceuticals (ASX:BOT): Healthcare Stock Keeps Traders Watching Beyond the Chart

Anixa Biosciences (ANIX) director adds 2,836 shares in open-market buy

Nutanix (NTNX): Buy, Sell, or Hold Post Q1 Earnings?

Nutanix (NTNX) Reports Earnings Beat. Here’s Why It Is Still Among The Most Shorted Cloud Stocks?

ANIX Q1 2026 Earnings: Narrower-than-expected loss highlights disciplined spending amid clinical development - Book Value Growth

ANIX Q1 2026 Earnings: EPS Surpasses Estimates as Loss Narrower Than Expected - Revenue Guidance Update

Nutanix (NTNX) Earnings Jump And 10% Margin Reinforce Bullish Profitability Narrative

Earnings call transcript: Nutanix exceeds Q3 2026 forecasts, stock dips

Nutanix (NTNX) Q3 Earnings and Revenues Top Estimates

Nutanix Earnings: What To Look For From NTNX

How Will Nutanix Stock React To Its Upcoming Earnings?

Nutanix (NTNX) Q3 Earnings on the Horizon: Analysts' Insights on Key Performance Measures

Botanix Pharmaceuticals (ASX:BOT) Shares Jump Today- What’s Driving the Momentum?

Earnings call transcript: Botanix Pharmaceuticals Q3 2026 sees revenue growth

A Look At Nutanix (NTNX) Valuation After Strong Revenue And Weaker Outlook Guidance

Q4 Earnings Outperformers: Nutanix (NASDAQ:NTNX) And The Rest Of The Cloud Monitoring Stocks

We're Not Very Worried About Anixa Biosciences' (NASDAQ:ANIX) Cash Burn Rate

Botanix Pharmaceuticals (ASX: BOT): FDA Approval Potential vs Commercial Execution Risk

Nutanix Stock At Risk Of Breaking Below $50 For First Time In A Year On Weak Outlook

Nutanix tops all Q2 targets but sees revenue delayed by supply strains

Evaluating Botanix Pharmaceuticals (ASX:BOT) After A$45 Million Equity Raise For Sofdra Rollout